QTTB — Q32 Bio Income Statement
0.000.00%
- $352.43m
- $229.61m
- $1.16m
Annual income statement for Q32 Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.67 | 2.7 | 34 | 3.21 | 1.16 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 112 | 133 | 130 | 5.24 | 93.8 |
Operating Profit | -110 | -130 | -95.9 | -2.03 | -92.7 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -104 | -129 | -95.8 | 1.2 | -87.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -104 | -129 | -95.8 | 0.483 | -87.1 |
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -104 | -129 | -95.8 | -5 | -113 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -104 | -129 | -95.8 | -5 | -113 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -44.4 | -50.5 | -31.2 | -28.3 | -35 |